Home LiteratureArticle Details
PMID: 18695749 Published · ppublish English Journal Article

Mechanisms by which diabetes increases cardiovascular disease.

Drug discovery today. Disease mechanisms ·Vol. 4 ·No. 3 ·2007-00-00 ·Pages 131-140

Gleissner CA, Galkina E, Nadler JL, Ley K

Abstract

Diabetes mellitus is one of the major risk factors for cardiovascular disease which is the leading cause of death in the U.S. Increasing prevalence of diabetes and diabetic atherosclerosis makes identification of molecular mechanisms by which diabetes promotes atherogenesis an important task. Targeting common pathways may ameliorate both diseases. This review focuses on well known as well as newly discovered mechanisms which may represent promising therapeutic targets.

Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Gleissner Christian A
Division of Inflammation Biology, La Jolla Institute for Allergy & Immunology, 9420 Athena Circle Drive, La Jolla, CA 92037.
Galkina Elena
Nadler Jerry L
Ley Klaus
References (74)
74 references, click to expand
  1. Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation.
    Clin Endocrinol (Oxf). 1998 Apr;48(4):515-20 PMID: 9640420
  2. The two faces of the 15-lipoxygenase in atherosclerosis.
    Prostaglandins Leukot Essent Fatty Acids. 2007 Aug;77(2):67-77 PMID: 17869078
  3. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin.
    FASEB J. 2003 Aug;17(11):1434-40 PMID: 12890697
  4. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.
    FASEB J. 2002 Dec;16(14):1928-30 PMID: 12368225
  5. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice.
    J Clin Invest. 1999 May 15;103(10):1431-6 PMID: 10330425
  6. Adipose tissue as an endocrine organ.
    J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56 PMID: 15181022
  7. New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy.
    Obesity (Silver Spring). 2006 Feb;14 Suppl 1:34S-40S PMID: 16642961
  8. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.
    J Clin Invest. 2005 Sep;115(9):2434-43 PMID: 16127462
  9. Insulin and glucose play a role in foam cell formation and function.
    Cardiovasc Diabetol. 2006 Jun 20;5:13 PMID: 16787541
  10. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Circ Res. 1999 Mar 19;84(5):489-97 PMID: 10082470
  11. In vivo action of 15-lipoxygenase in early stages of human atherogenesis.
    J Clin Invest. 1997 Mar 1;99(5):888-93 PMID: 9062346
  12. The role of protein kinase C activation and the vascular complications of diabetes.
    Pharmacol Res. 2007 Jun;55(6):498-510 PMID: 17574431
  13. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Circulation. 2006 Aug 8;114(6):597-605 PMID: 16894049
  14. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells.
    FASEB J. 1997 Feb;11(2):181-8 PMID: 9039961
  15. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
    Nature. 2007 Jun 21;447(7147):959-65 PMID: 17554340
  16. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    Diabetologia. 2005 Sep;48(9):1684-99 PMID: 16079964
  17. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2.
    Circ Res. 2006 Nov 24;99(11):1181-7 PMID: 17068290
  18. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein.
    Science. 1996 Nov 22;274(5291):1377-9 PMID: 8910278
  19. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.
    Atherosclerosis. 2005 Aug;181(2):251-9 PMID: 16039278
  20. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Diabetes Care. 2006 Jul;29(7):1538-44 PMID: 16801576
  21. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.
    Circulation. 2002 Nov 26;106(22):2767-70 PMID: 12451000
  22. An update on the etiology and epidemiology of diabetes mellitus.
    Ann N Y Acad Sci. 2006 Nov;1084:1-29 PMID: 17151290
  23. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications.
    Curr Med Chem. 2003 Aug;10(15):1389-98 PMID: 12871136
  24. Insulin resistance and atherosclerosis in diabetes mellitus.
    Metabolism. 2002 Aug;51(8):941-8 PMID: 12145764
  25. Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties.
    Biochim Biophys Acta. 1986 Mar 28;870(2):302-11 PMID: 3082363
  26. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
    Circulation. 2005 Nov 8;112(19):3001-8 PMID: 16260636
  27. Optimizing cardiovascular outcomes in diabetes mellitus.
    Am J Med. 2007 Sep;120(9 Suppl 2):S3-11 PMID: 17826044
  28. Standards of medical care in diabetes--2007.
    Diabetes Care. 2007 Jan;30 Suppl 1:S4-S41 PMID: 17192377
  29. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.
    Vasc Health Risk Manag. 2005;1(1):19-28 PMID: 17319095
  30. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.
    J Clin Invest. 2005 Aug;115(8):2192-201 PMID: 16075060
  31. The immunogenicity of modified lipoproteins.
    Ann N Y Acad Sci. 2005 Jun;1043:367-78 PMID: 16037258
  32. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9 PMID: 15356026
  33. Serum lipoprotein lipase mass: clinical significance of its measurement.
    Clin Chim Acta. 2007 Mar;378(1-2):7-12 PMID: 17223095
  34. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.
    J Am Coll Cardiol. 2003 Apr 2;41(7):1198-204 PMID: 12679222
  35. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes.
    Diabetes. 2007 Feb;56(2):499-505 PMID: 17259397
  36. Biochemistry and molecular cell biology of diabetic complications.
    Nature. 2001 Dec 13;414(6865):813-20 PMID: 11742414
  37. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    N Engl J Med. 2007 Jun 14;356(24):2457-71 PMID: 17517853
  38. Lipid inflammatory mediators in diabetic vascular disease.
    Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1542-8 PMID: 15166011
  39. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes.
    Atherosclerosis. 2006 Mar;185(1):70-7 PMID: 16076470
  40. Inflammatory mechanisms of diabetic complications.
    Curr Diab Rep. 2007 Jun;7(3):242-8 PMID: 17547842
  41. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis.
    Am J Pathol. 2007 Nov;171(5):1705-12 PMID: 17884970
  42. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.
    J Clin Invest. 2001 Nov;108(9):1341-8 PMID: 11696579
  43. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells.
    Circ Res. 1997 Dec;81(6):953-62 PMID: 9400375
  44. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
    Biochem Biophys Res Commun. 2004 May 21;318(1):265-74 PMID: 15110783
  45. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
    Circulation. 2004 Jan 27;109(3):433-8 PMID: 14744958
  46. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.
    Circulation. 1999 Dec 21-28;100(25):2473-6 PMID: 10604883
  47. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis.
    Nat Med. 2001 Jun;7(6):699-705 PMID: 11385507
  48. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice.
    Circulation. 2001 Oct 2;104(14):1646-50 PMID: 11581143
  49. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity.
    Atherosclerosis. 2004 Jun;174(2):385-90 PMID: 15136071
  50. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.
    Diabetes Care. 2004 Nov;27(11):2767 PMID: 15505023
  51. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance.
    Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):487-96 PMID: 15637306
  52. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation.
    Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12222-6 PMID: 11050244
  53. Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation.
    Biochem Biophys Res Commun. 2007 May 18;356(4):1024-30 PMID: 17399685
  54. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18.
    Endothelium. 1999;6(4):315-24 PMID: 10475094
  55. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Am J Cardiol. 2007 Feb 19;99(4A):27B-40B PMID: 17307056
  56. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice.
    Atherosclerosis. 2008 Jan;196(1):68-75 PMID: 17362969
  57. Inflammation, atherosclerosis, and coronary artery disease.
    N Engl J Med. 2005 Apr 21;352(16):1685-95 PMID: 15843671
  58. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
    Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):540-5 PMID: 14707040
  59. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
    Circ Res. 2004 Jun 11;94(11):1515-22 PMID: 15117825
  60. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice.
    Circulation. 2001 May 8;103(18):2277-82 PMID: 11342477
  61. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages.
    Atherosclerosis. 2002 Dec;165(2):259-69 PMID: 12417276
  62. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis.
    J Lipid Res. 2006 Oct;47(10):2215-22 PMID: 16840797
  63. Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study.
    Diabetes. 2005 Apr;54(4):1228-32 PMID: 15793266
  64. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction.
    Diabetes. 2005 Oct;54(10):3021-5 PMID: 16186408
  65. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes.
    Diabetes. 2007 Mar;56(3):647-55 PMID: 17327432
  66. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
    Circulation. 2007 Feb 6;115(5):e69-171 PMID: 17194875
  67. Aldose reductase inhibitors.
    J Enzyme Inhib. 2001 Dec;16(6):465-73 PMID: 12164386
  68. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation.
    Clin Chim Acta. 2000 Nov;301(1-2):65-77 PMID: 11020463
  69. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
    Nat Genet. 2000 Sep;26(1):76-80 PMID: 10973253
  70. Novel inhibitors of advanced glycation endproducts.
    Arch Biochem Biophys. 2003 Nov 1;419(1):63-79 PMID: 14568010
  71. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases.
    J Biol Chem. 1989 Jun 5;264(16):9547-51 PMID: 2498333
  72. Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis.
    Cardiovasc Diabetol. 2005 Oct 05;4:16 PMID: 16207378
  73. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.
    Circulation. 2002 Nov 26;106(22):2827-35 PMID: 12451010
  74. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
    Diabetes. 2006 Jan;55(1):110-9 PMID: 16380483
Article Info
Journal
Drug discovery today. Disease mechanisms
Abbr.
Drug Discov Today Dis Mech
ISSN
1740-6765
DOI
10.1016/j.ddmec.2007.12.005
Published
2007-00-00
Pages
131-140
Language
English
Region
England
NLM ID
101235075
PMCID
PMC2504760
Grants
NHLBI NIH HHS · P01 HL055798-120009 · United States
NHLBI NIH HHS · R01 HL058108-10 · United States
NHLBI NIH HHS · P01 HL055798-110009 · United States
NHLBI NIH HHS · R01 HL058108 · United States
NHLBI NIH HHS · R01 HL058108-11 · United States
NHLBI NIH HHS · P01 HL055798 · United States
External Links
PubMed source DOI: 10.1016/j.ddmec.2007.12.005 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2